Obesity trials are evolving amid $30 billion global investment in 2024, focusing on complex endpoints and patient-centric designs. Sponsors emphasize integrating digital tools like eCOAs, connected devices, and analytics with behavioral science to improve trial agility and data quality. This strategic blend aims to overcome retention challenges heightened by obesity-related factors, advancing therapeutic development with enhanced patient experience capture.